IR Overview

Webcast ImageWebcast
Adaptimmune Data Update on NY-ESO SPEAR T-cells in Synovial Sarcoma; ASCO 2017 (Live)
06/06/17 at 8:00 a.m. ET
Adaptimmune Data Update on NY-ESO SPEAR T-cells in Synovial Sarcoma; ASCO 2017
Tuesday, June 6, 2017 8:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Thank you for your interest in Adaptimmune. We are a leader in the TCR T-cell therapy space focused on novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). The result of our efforts are SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell therapies that can recognize cancer proteins, and as a result detect and fight cancer within patients.


SPEAR T-cell therapies targeting MAGE-A10, MAGE-A4, AFP and NY-ESO are moving into and through clinical studies. In addition to the targets for which clinical and preclinical evaluation is ongoing, we have identified over 30 intracellular target peptides preferentially expressed in cancer cells and are currently progressing 12 through unpartnered research programs.

$5.32 Stock is Up 0.02 (0.38%)
ADAP (American Depositary Shares)
ExchangeNASDAQ GS (US Dollar)
Volume202,202
Today's Open$5.30
Previous Close$5.30
Data as of 05/26/17 4:00 p.m.
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Recent NewsMore >>
DateTitle 
05/26/17Adaptimmune Announces an Oral Presentation and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual Meeting
PHILADELPHIA and OXFORD, United Kingdom, May 26, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced an oral presentation, as well as four trials in progress posters, at the 2017 ASCO annual meeting in Chicago, Illinois on June 2 through June 6, 2017. During an oral presentation scheduled for 1:15-1:27 PM CDT on June 5th, Dr. Sandra P. D’Angelo of the Memorial Sloan Kettering Cancer Center will present a full updat... 
Printer Friendly Version
05/25/17Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting NY-ESO in Combination with KEYTRUDA® (pembrolizumab) in Multiple Myeloma
PHILADELPHIA and OXFORD, United Kingdom, May 25, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated its study of NY-ESO SPEAR T‑cells targeting NY-ESO in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 inhibitor marketed by Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada), in patients with multiple myeloma. This study is now open for enrollment. Thi... 
Printer Friendly Version
05/16/17Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors
PHILADELPHIA and OXFORD, U.K., May 16, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated the first site for its MAGE‑A4 SPEAR T-cell study in patients with multiple malignant solid tumors. This study is now open for enrollment. This is Adaptimmune’s third wholly-owned therapeutic candidate to enter clinical trials. The Company already has ongoing studies to evaluate its T-cell therapies target... 
Printer Friendly Version
05/10/17Adaptimmune Reports First Quarter 2017 Financial Results
– Offerings in March and April raised net proceeds of $103.2 million; operations funded through to late 2019 – – Initiated study with wholly-owned AFP SPEAR T-cells – – Initial data from three wholly-owned assets (MAGE-A4, MAGE-A10, and AFP) in up to eight tumor indications anticipated in 2017 and 2018 – – Updated NY-ESO data to be presented in an oral presentation at the upcoming Annual American Society of Clinical Oncology (ASCO) Meeting – PHILADELPHIA and OXFORD, U.K., May 10, 2017 (GLO... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
06/06/17 8:00 a.m. ET
Adaptimmune Data Update on NY-ESO SPEAR T-cells in Synovial Sarcoma; ASCO 2017
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Adaptimmune posts new information to the site. Just enter your e-mail address and click Submit.